- Stocks
- Healthcare
- NASDAQ: SRDX

Price (delayed)

$39.49

Market cap

$563.4M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.09

Enterprise value

$568.62M

Surmodics is the global leader in surface modification technologies for intravascular medical devices and a leading provider of chemical components for in vitro diagnostic (IVD) immunoassay tests and microarrays. Surmodics

The net income has dropped by 110% since the previous quarter but it has surged by 94% year-on-year

The company's EPS has shrunk by 109% QoQ but it has surged by 95% YoY

The gross profit is down by 21% since the previous quarter and by 16% year-on-year

SRDX's revenue is down by 15% QoQ and by 7% YoY

What are the main financial stats of SRDX

Market
Valuations
Earnings

Shares outstanding

14.27M

Market cap

$563.4M

Enterprise value

$568.62M

Price to book (P/B)

4.77

Price to sales (P/S)

4.63

EV/EBIT

N/A

EV/EBITDA

146.89

EV/Sales

4.71

Revenue

$120.82M

EBIT

-$5.61M

EBITDA

$3.87M

Free cash flow

-$5.86M

Per share
Balance sheet
Liquidity

EPS

-$0.09

Free cash flow per share

-$0.41

Book value per share

$8.28

Revenue per share

$8.53

TBVPS

$7.79

Total assets

$177.41M

Total liabilities

$59.27M

Debt

$29.52M

Equity

$118.14M

Working capital

$60.16M

Debt to equity

0.25

Current ratio

3.98

Quick ratio

2.55

Net debt/EBITDA

1.35

Margins
Efficiency
Dividend

EBITDA margin

3.2%

Gross margin

74%

Net margin

-1.2%

Operating margin

-6.2%

Return on assets

-0.8%

Return on equity

-1.2%

Return on invested capital

-6.1%

Return on capital employed

-3.6%

Return on sales

-4.6%

Dividend yield

N/A

DPS

N/A

Payout ratio

N/A

How has the Surmodics stock price performed over time

Intraday

0.59%

1 week

0.66%

1 month

-1.42%

1 year

16.9%

YTD

8.64%

QTD

-6.07%

How have Surmodics's revenue and profit performed over time

Revenue

$120.82M

Gross profit

$89.43M

Operating income

-$7.48M

Net income

-$1.4M

Gross margin

74%

Net margin

-1.2%

SRDX's operating margin has dropped by 148% since the previous quarter

The operating income has plunged by 141% from the previous quarter

The net margin has dropped by 113% since the previous quarter but it has soared by 93% year-on-year

The net income has dropped by 110% since the previous quarter but it has surged by 94% year-on-year

What is Surmodics's growth rate over time

What is Surmodics stock price valuation

P/E

N/A

P/B

4.77

P/S

4.63

EV/EBIT

N/A

EV/EBITDA

146.89

EV/Sales

4.71

The company's EPS has shrunk by 109% QoQ but it has surged by 95% YoY

The stock's price to book (P/B) is 16% more than its last 4 quarters average of 4.1 and 8% more than its 5-year quarterly average of 4.4

Surmodics's equity has increased by 5% YoY but it has decreased by 4.7% QoQ

SRDX's P/S is 24% above its last 4 quarters average of 3.7 but 12% below its 5-year quarterly average of 5.2

SRDX's revenue is down by 15% QoQ and by 7% YoY

How efficient is Surmodics business performance

The company's return on sales has shrunk by 132% QoQ

The ROIC has plunged by 125% from the previous quarter

SRDX's return on assets has dropped by 111% since the previous quarter but it has surged by 94% year-on-year

The ROE has plunged by 111% from the previous quarter but it has soared by 94% YoY

What is SRDX's dividend

DPS

N/A

Dividend yield

N/A

Payout ratio

N/A

There are no recent dividends present for SRDX.

How did Surmodics financials performed over time

The total assets is 199% more than the total liabilities

The current ratio has grown by 49% YoY but it has contracted by 9% from the previous quarter

SRDX's quick ratio is up by 45% year-on-year but it is down by 8% since the previous quarter

The debt is 75% smaller than the equity

Surmodics's equity has increased by 5% YoY but it has decreased by 4.7% QoQ

The debt to equity has grown by 4.2% from the previous quarter but it has contracted by 3.8% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified. Data from and Sharadar.